Condition
Frontal fibrosing alopecia
A scarring hair loss that pulls the front and temple hairline back, often with eyebrow thinning; lost follicles do not return, so treatment aims to stop progression early.
Key takeaways
- Frontal fibrosing alopecia (FFA) is a scarring hair loss that pulls the front and temple hairline back, often with eyebrow thinning. It is a variant of the lichen planopilaris spectrum (Starace 2025). Lost follicles do not come back, so the goal is to stop progression early.
- It is not just a receding hairline. In men it is regularly misdiagnosed as pattern hair loss or alopecia areata; early beard and sideburn involvement and eyebrow loss (43 to 94.9% in reviewed series) are clues (Melian-Olivera 2025).
- The best-supported medical option is oral dutasteride plus topical or injected steroids. A 2024 meta-analysis of 7 non-randomized studies (366 patients) estimated 63% stabilized, with about 36% of the stabilized group improving (Seo 2024). Quality is low, with no randomized trials, and methodological concerns have been raised (Pedroso Junges 2025).
- A 2025 Spanish expert consensus recommends combining treatments, starting with oral dutasteride plus topical or injected agents, and adding hydroxychloroquine if inflammation persists (Saceda-Corralo 2026).
- No treatment is approved for FFA in the US, EU or UK. Everything is off-label and prescription-only.
- Triggers are unproven. Facial sunscreens, moisturizers and hair products have been implicated, but one 2025 case-control study found no sunscreen association (Ko 2025). Do not stop sunscreen on this evidence.
- Transplants are a gamble. In a 2026 systematic review (113 patients with FFA or lichen planopilaris), graft survival was 80 to 100% at 6 to 12 months but under 41% after year 2 (Palacios-Diaz 2026).
What it is
FFA involves an immune attack on the upper follicle with replacement by scar. It was first described in 1994 and is now seen more often, mainly in postmenopausal women (Saceda-Corralo 2026). Genetic and possible environmental contributions are discussed in reviews.
Hair-care habits: in 115 patients versus 112 matched controls in Argentina, washing at most once a week was linked to higher odds (adjusted OR 18.7 against daily washing), as were cosmetic procedures twice a year or more (OR 2.39) and weekly leave-in products (OR 4.98). This is case-control and self-reported, so it cannot show cause, and it does not mean washing treats FFA (Ko 2025).
What the studies show
| Option | Evidence |
|---|---|
| Oral dutasteride | Meta-analysis of 7 non-randomized studies, 366 patients; off-label, pregnancy risk |
| Oral finasteride | Same drug family, smaller data |
| Topical or injected steroids, tacrolimus | Consensus and series |
| Hydroxychloroquine | Series |
| Topical minoxidil | Supportive only, not stand-alone |
| Delgocitinib cream | Phase 2a trial of 30 women over 12 weeks lowered an inflammation marker; exploratory, small, with a company co-author (Martin 2026) |
| Hair transplant | Case series; only when disease is quiet |
A systematic review of 38 studies (411 patients) of lichen planopilaris and FFA procedures found platelet products most consistently reduced activity scores, low-level light gave modest gains and steroid injections stabilized disease, mostly in small series (Tanha 2025). See PRP and low-level laser therapy.
Hair type notes
- In textured hair FFA has distinct features and is easily mistaken for traction alopecia or CCCA (Geisler 2024). If a traction hairline keeps receding after you loosen styles, ask for a biopsy.
- In men, beard, sideburn and eyebrow loss with a receding line is a red flag.
Bottom line
Frontal recession with eyebrow loss, scalp burning or itch, tiny bumps on the forehead or a smooth shiny hairline needs a dermatologist promptly (see when to see a dermatologist). Do not delay for products or supplements, none of which has FFA data. Photograph hairline and brows monthly. Treatment must continue, since loss returns if it stops. Dutasteride and finasteride are not options in pregnancy. Related: lichen planopilaris, traction alopecia. Discuss with a doctor.
Studies 10
Starace MVR et al. Delphi consensus on the distinct clinical and histopathological features of lichen planopilaris and frontal fibrosing alopecia. Int J Dermatol. 2025
Tested: Delphi consensus
Result: Frontal fibrosing alopecia is treated as a variant on the lichen planopilaris spectrum.
Read the study ↗Melian-Olivera A et al. Frontal fibrosing alopecia in men: a review of the literature. J Clin Med. 2025
Tested: review
Result: Often misdiagnosed as pattern hair loss or alopecia areata; eyebrow loss in 43-94.9% of reviewed series and early beard and sideburn involvement are clues.
Read the study ↗Seo HM et al. Dutasteride in the treatment of frontal fibrosing alopecia: systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2024
Tested: oral dutasteride
Result: About 63% stabilized, with about 36% of those improving; low-quality evidence.
Read the study ↗Pedroso Junges AP et al. Methodological concerns in 'dutasteride in the treatment of frontal fibrosing alopecia'. J Eur Acad Dermatol Venereol. 2025
Tested: methodological critique
Result: Raised methodological concerns about the dutasteride meta-analysis.
Read the study ↗Saceda-Corralo D et al. Consensus document on the clinical management of frontal fibrosing alopecia (AEDV). Actas Dermosifiliogr. 2026
Tested: management consensus
Result: Recommends combining oral dutasteride with topical or injected agents, adding hydroxychloroquine if inflammation persists.
Read the study ↗Ko EA et al. Hair care habits and frontal fibrosing alopecia: a case-control study. Skin Appendage Disord. 2025
Tested: hair care habit comparison
Result: Washing at most weekly (adjusted OR 18.7), cosmetic procedures twice a year or more (OR 2.39) and weekly leave-in products (OR 4.98) raised odds; no sunscreen association; cannot show cause.
Read the study ↗Show 4 more studies
Martin A et al. Randomized controlled trial of topical JAK inhibitor delgocitinib cream in frontal fibrosing alopecia. J Invest Dermatol. 2026
Tested: delgocitinib 2% cream vs vehicle
Result: Lowered the inflammatory marker CXCL9 and slightly improved gene-expression profile (4%) while vehicle worsened (33%); small, exploratory, company co-author.
Read the study ↗Tanha AE et al. Systematic review of procedural modalities in lichen planopilaris, frontal fibrosing alopecia and discoid lupus erythematosus. Lasers Med Sci. 2025
Tested: PRP, low-level light, steroid injections, transplant
Result: Platelet products most consistently reduced activity scores; light gave modest gains; steroid injections stabilized disease with inconsistent regrowth; transplant worked early with graft loss by 3-5 years.
Read the study ↗Palacios-Diaz RD, Lasheras-Perez MA. Systematic review of efficacy of hair transplantation in patients with classic lichen planopilaris and frontal fibrosing alopecia. An Bras Dermatol. 2026
Tested: hair transplantation
Result: Graft survival fell below 41% after year 2.
Read the study ↗Geisler AN et al. Updates on disorders in curly hair. 2024
Result: Review of hair care practices: high-tension styles cause traction alopecia and grooming drives trichorrhexis nodosa.
Read the study ↗Related
- Lichen planopilarisAn immune-mediated scarring hair loss, mainly on the crown and sides, that destroys follicles permanently; early treatment aims to stop activity because lost hair does not return.
- Traction alopeciaHair loss from repeated or constant pulling on the follicle by tight braids, weaves, buns or ponytails; it starts reversible but can become permanent if the tension continues.
- Central centrifugal cicatricial alopecia (CCCA)The most common scarring hair loss in women of African descent, starting at the crown and spreading outward; early diagnosis matters because lost follicles are replaced by scar.
- DutasterideA stronger cousin of finasteride that blocks both forms of the DHT-making enzyme and grew more hair than finasteride in head-to-head trials.
- FinasterideA prescription pill (and in some countries a scalp spray) that lowers DHT and is the best-proven drug for stopping male pattern hair loss.
- MinoxidilThe most widely used hair-growth treatment, available as a cheap over-the-counter lotion or foam and as a prescription tablet, with a mechanism that is still only partly understood.
- Platelet-rich plasma (PRP) for hair lossYour own blood is spun to concentrate platelets and injected into the scalp; pooled trials show a modest gain, but individual trials conflict and each session is costly.
- Low-level laser therapy (red-light caps, combs and helmets)Red-light lasers and LEDs worn as caps, combs or helmets add a modest amount of hair over sham devices in mostly industry-funded trials.
- When to see a dermatologistMost gradual thinning is pattern loss you can start treating yourself, but scarring signs, scalp symptoms, patches or sudden shedding should go to a clinician quickly because delay can cost permanent hair.